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ABSTRACT
Objectives: This study measured the treatment cost of
bipolar disorder (BPD), decomposed the cost into that
portion which was directly BPD-related and that attribut-
able to comorbidities, and compared health-care utilization
and costs across groups of patients with different drug
regimens.
Methods: Using a multistate managed-care-organization
claims database, a cohort of 67,862 BPD patients were
selected and followed for the length of their enrollment
between January 1, 1998 and December 31, 2002. All costs
associated with the patients’ medical claims were adjusted to
2002 dollars using the medical component of Consumer Price
Index. Patients were classiﬁed into three groups based on
their drug regimen: atypical antipsychotics (ATYP), atypical
antipsychotics plus mood stabilizers (ATYP + MS), and
mood stabilizers only (MS). The Charlson comorbidity index
was used to control for comorbid conditions. Using both
Poisson and log-linear regression analyses, numbers of
hospitalizations, emergency room (ER) visits, and outpatient
visits, as well as treatment costs per enrolled month, were
regressed on age, sex, medication regimen, and clinical
comorbidities.
Results: The mean charge and reimbursement per patient-
year were $12,797 and $6581, respectively. Of the treatment
cost, 33% was BPD-related, and 67% was attributed to
comorbidities. Compared to patients in the MS treatment
regimen, higher treatment costs were associated with ATYP
(Rate Ratio = 1.24, 95% CI 1.17–1.31) and ATYP + MS
(RR = 1.52, 1.47–1.56). Moreover, higher costs were asso-
ciated with key comorbidities like personality disorder
(RR = 1.45, 1.37–1.53). Patients on the ATYP regimen had
higher risks of hospitalization (RR = 1.44, 1.33–1.56) and
ER visits (RR = 1.15, 1.04–1.27), but lower risk of out-
patient visits (RR = 0.81, 0.76–0.86).
Conclusions: Controlling treatment costs for BPD patients
requires focusing on patients with key comorbidities and
monitoring the association between treatment regimen and
resource use.
Keywords: bipolar disorder, comorbidities, health care utili-
zation, treatment cost.
Introduction
Bipolar disorder (BPD), also known as manic-
depressive illness, affects more than 2.6% of the U.S.
adult population [1,2]. BPD is commonly associated
with both psychiatric (e.g., anxiety, substance abuse,
and personality disorders) [3–12] and medical (e.g.,
hypertension, diabetes, and obesity) comorbidities
[5,13–15]. The economic burden of BPD is substantial.
The annual cost of bipolar disorder in the U.S. was
estimated in 1991 to be $45 billion, including $7
billion for direct treatment-related costs [16].
Based on insurance claims data from 1998 and
2000, an adult patient with BPD spends between
$7200 and $12,100 per year, including about 15%
on prescription drugs, 20% on hospitalization(s),
and 25% on physician visits and other medical care
[17,18]. Alternatively, combining the $7 billion in
treatment charges [16] and ECA survey prevalence
data (600,000 patients) [19], the annual treatment
charge per patient was estimated as $11,700 in 1991.
With a three percent annual inﬂation rate, this estimate
translates to approximately $16,000 in 2002 US.
dollars. Finally, based on the reported treatment
charge of $12,200 in 1996 for a patient with bipolar I
[17], we get a third annual estimate of approximately
$14,500 in 2002 dollars, again assuming a three
percent annual inﬂation rate.
Our ﬁrst objective in this paper is to produce a
carefully constructed annual cost estimate along these
lines, based on a large managed care claims database.
Besides costs, we also measure annual resource
utilization by assessing, among other measures of
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health-care use, the number of hospitalizations and
emergency room visits. Our second objective is to
decompose total utilization and cost into the share
accounted for by the bipolar disease itself and the
share related to various comorbidities, in order to
give managed care organizations and third-party
payers a better understanding of utilization and cost
origins.
Finally, we seek to understand speciﬁcally the effect
of treatment regimen on health care utilization and
cost. Medication is an essential part of successful treat-
ment for bipolar disorder. The conventional mood sta-
bilizer lithium is commonly used for bipolar treatment,
while emergent therapies include lamotrigine, carbam-
azepine, and atypical antipsychotics [20,21]. More-
over, patients with BPD often receive antidepressants
during depressive episodes and as a component of
maintenance treatment. Recent prescription data indi-
cate that between 42% and 64% of BPD patients
receive traditional mood stabilizers (e.g., lithium, val-
proic acid, carbamazepine), and 44% to 60% receive
antipsychotic augmentation therapy [22–24]. This
increased utilization of antipsychotics is due to their
antimanic or mood-stabilizing properties as well as to
their more favorable tolerability proﬁles compared
with conventional agents [22,23]. In addition, antip-
sychotic medications share several characteristics with
antidepressants, i.e., serotonin (5-HT) and norepi-
nepherine reuptake inhibitors, and 5HT-1 A receptor
agonism [21,25–27]. Finally, recent clinical trials indi-
cate that antipsychotic augmentation might also be
efﬁcacious for the treatment of bipolar depression
[25–27].
Our third objective is to compare utilization and
cost across different treatment regimens for bipolar
disorder, controlling, to the best of our ability, for
different patient characteristics. While managed care
organizations and other third-party payers have faced
steeply rising costs over time for atypical antipsychot-
ics, it is important to appreciate their beneﬁt, if any, in
reducing expensive emergency room visits and hospi-
talizations. As a result of this study, we will be able to
shed some light on the question of whether antipsy-
chotics reduce overall costs and utilization for bipolar
patients, adding to an already interesting debate in the
literature.
Patients and Methods
Study Design and Data Source
A retrospective cohort study was conducted. The study
period was from January 1, 1998, to December 31,
2002 (5 calendar years). The primary data source is a
multistate managed care medical claims database
(PHARMetrics, http://www.Pharmetrics.com) which
includes several states in the Midwest, Northeast,
Southern and Western regions of the U.S. This
database covers over 45 million individuals who are
enrolled in 70 different health plans in managed care
organizations. The claims database includes all phar-
macy, medical, and institutional claims administered
by managed care organizations. Each medical claim
was recorded with accompanying diagnostic codes
(International Classiﬁcation of Diseases, Ninth Revi-
sion [ICD-9]) that justiﬁed the medical service. To
protect patient conﬁdentiality, patient names, insur-
ance plan identiﬁcation numbers, and other patient
identiﬁers were deleted from the claims database. We
used randomized patient numbers and birth years
to conduct data analyses. This study design was
approved by the Institutional Review Board (IRB) of
the University of Cincinnati Medical Center.
Patient Selection
We started with 709,865 patients who had at least one
medical claim with a diagnosis of affective disorder
(ICD-9 = 296.xx) or cyclothymia (ICD-9 = 301.13).
We then excluded Medicaid recipients (44,095) due to
their unique socioeconomic and demographic charac-
teristics, patients with schizophrenia (15,199) who
have been studied elsewhere in the literature, and
patients with epilepsy (1389) who take some of the
same anticonvulsants as those prescribed for BPD.
Patients (527,279) who had only depression diagnoses
(ICD-9 codes = 311, 296.2x, and 296.3x) were also
excluded. Although some of these individuals may be
expected to be diagnosed as bipolar eventually, during
the time period for this study no conclusive evidence of
bipolar disorder was available. After these exclusions,
we were left with a total of 121,903 patients who
received at least one bipolar diagnosis indicated by
ICD9 codes 296.0, 296.1, and 296.4–296.8. The index
date of bipolar diagnosis was the ﬁrst date of diagnosis
indicated by a bipolar ICD-9 code during the study
period. Eligibility for the patient cohort was further
restricted to enrollees who had basic mental health
care coverage and who were enrolled in a plan in the
database for at least three months following their
bipolar index date. Finally, to be included in the
cohort, a patient must have received at least one pre-
scription for bipolar treatment from a list of medica-
tions, including mood stabilizers (lithium, valproate,
carbamazepine, lamotrigine), antidepressants (selec-
tive serotonin reuptake inhibitors, tricyclic agents, and
other antidepressants), and antipsychotics. This latter
restriction was required because of our third objective
to compare costs and utilization across treatment regi-
mens. After all exclusions, we were left with a study
cohort of 67,862 patients with BPD.
Study patients were further classiﬁed into three
groups based on their drug regimen from the bipolar
index date to either the end of enrollment or the end of
the study period, whichever occurred ﬁrst. Patients
were assigned to the ATYP group if they received only
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atypical antipsychotics (aripiprazole, risperidone, que-
tiapine, olanzapine, ziprasidone, or clozapine). They
were assigned to the MS group if they received only
mood stabilizers (lithium, valproate, carbamazepine,
or lamotrigine). Patients were assigned to the ATYP +
MS group if they received both types of medication.
We note that many patients in all three groups were
taking antidepressants for their depressive episodes as
well.
Deﬁnition of Utilization and Cost Variables
We look at a number of different utilization and cost
variables in our study. As our three primary measures
of utilization, we calculate the number of hospitaliza-
tions, the number of emergency room visits, and the
number of outpatient visits. We look as well at number
of prescriptions, laboratory tests, mental health ser-
vices, and other medical services. To standardize across
patients enrolled for different numbers of months
during the study period, we obtain average utilization
per patient per month by summing number of hospi-
talizations or visits, say, and then dividing the total by
the number of months of available data following the
index date.
For costs, we consider both amount charged and
amount reimbursed for hospitalizations, emergency
room visits, outpatient visits, mental health services,
physician encounters, prescription drugs, laboratory
tests, and other medical services. Whereas the amount
reimbursed represents cost to the insurance company,
the amount charged includes cost to the patient, and
may be compared more easily to estimates obtained in
other health care environments. Again, in order to
standardize across patients with different numbers of
months of enrollment during the study period, we
obtain average cost per patient per month by summing
charges or reimbursement amounts and dividing by the
number of months of available data following the
index date. For each medical claim from 1998 to 2002,
all costs were converted to 2002 US. dollars using the
medical component of the Consumer Price Index
(MCPI). The annual MCPI inﬂation rates were 5.4%
in 2001 to 2002, 4.2% in 2000 to 2001, 3.7% in 1999
to 2000, and 3.4% in 1998 to 1999 [28,29]. Note that
these values are conservative in the case of pharmaceu-
ticals; their prices rose considerably more during these
years.
All charges and reimbursements are further divided
into those directly related to the treatment of bipolar
disorder and those that are not. Bipolar-related treat-
ment costs include the following: all medical claims,
with any primary or secondary ICD9 code for bipolar
disorder, for hospitalizations, outpatient visits, and
physician encounters; some selected laboratory tests
indicated by the Current Procedural Terminology
(CPT) codes, including serum drug concentration tests,
complete blood and platelet counts (CBCs), chem-7
panels, thyroid function tests, liver function tests, uri-
nalysis, electrocardiography (ECG/EKG), pregnancy
tests, and glucose tests [30]; and pharmacy claims for
prescriptions for mood stabilizers, antidepressants,
and antipsychotics.
Covariates and Statistical Analysis
The literature suggests, and our results show (below),
that patients with bipolar disorder often have signiﬁ-
cant comorbidities which contribute to their demand
for health-care resources and their overall health-care
costs. Based on published literature, there are two
major types of clinical comorbidities: psychiatric dis-
orders and general medical comorbidities [11–15,24].
Psychiatric disorders include alcohol and substance use
disorders, anxiety disorders, impulse control disorders,
personality disorders, and eating disorders, all of
which we observed after the BPD index date. In
addition, we included other mental illnesses such as
depression and attention deﬁcit hyperactivity disorder
(ADHD). General medical comorbidities include
cerebral-vascular disease (CVS), ischemic heart disease
(IHD), arthritis, obesity, diabetes mellitus, hyperten-
sion, and chronic obstructive pulmonary disease
(COPD). All comorbidities were identiﬁed by their
ICD9 codes in either institutional or medical claims
ﬁles. All comorbidities were represented by dichoto-
mous variables in the statistical analyses. Age of BPD
onset for each patient was calculated as the index year
of bipolar diagnosis minus the patient’s birth year.
Since it is impossible to control for all comorbidities
individually, we also introduce Charlson comorbidity
index scores [31] in the analysis to capture other
comorbid conditions such as cancer, dementia, moder-
ate or severe liver disease, prior myocardial infarction,
moderate or severe renal disease, connective tissue
disease, ulcer disease, leukemia, lymphoma, and meta-
static solid tumors. The key clinical comorbidities
above, e.g., diabetes mellitus, hypertension, arthritis,
and obesity, associated with bipolar disorder were not
included in the Charlson index scores to avoid double
counting.
A preliminary data analysis showed that both treat-
ment cost and utilization data were highly skewed
distributions due to high-cost outliers, nonusers, and
different enrollment durations. Hence, Poisson regres-
sion analysis [32] was used to assess the risk of inpa-
tient hospitalizations, outpatient visits, and ER visits.
Using both log-linear and Poisson regression analyses
(since the Poisson model is most appropriate for count,
rather than continuous, dependent-variable data), the
treatment cost per enrolled month was regressed on
age, sex, drug regimen, psychiatric and medical comor-
bidities, and the Charlson index score. All statistical
analyses were conducted using SAS for Windows,
version 9.1.
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Results
Demographics and Use of Medications
Of the 67,862 patients with BPD in this cohort, 62%
are female. The mean age is 37.1 (SD = 15.0,
median = 38.0) years, and the mean (SD) months of
enrollment in managed care is 26.5 (14.8) months (see
Table 1). Key comorbidities include anxiety disorder
(40%), hypertension (19%), diabetes mellitus (8%),
alcohol abuse (7%), substance abuse (6%), and
obesity (6%).
Treatment Costs
The mean charge and reimbursement per patient-year
are $12,797 and $6581, respectively, in 2002 US.
dollars (see Table 2). Key cost components include
inpatient care (31%), outpatient visits (16%), pre-
scription drugs (24%), and physician encounters
(16%). ER visits make up only 3% of total costs.
Of total treatment costs, 33% are bipolar-related
expenses, while the remaining 67% can be accounted
for by the treatment of comorbidities.
Compared to patients on the MS regimen, the
ATYP patients have an estimated 24% higher cost
(Rate Ratio = 1.24, 95% CI 1.17–1.31), while patients
taking both mood stabilizers and atypical antipsychot-
ics (those in the ATYP + MS group) have an estimated
52% higher cost (RR = 1.52, 1.47–1.56). Several key
comorbidities like personality disorder (RR = 1.45,
1.37–1.53), substance abuse (RR = 1.44, 1.37–1.52),
and ischemic heart disease (RR = 1.49, 1.42–1.56) add
substantially to treatment cost (see Table 3).
Health Care Utilization
Patients taking atypicals have higher risks of hospi-
talization (RR = 1.44, 1.33–1.56) and (RR = 1.61,
1.54–1.68) and ER visits (RR = 1.15, 1.04–1.27) and
(RR = 1.41, 1.34–1.48) (see Table 4). Interestingly,
patients with the ATYP regimen are seen to have a
lower risk of outpatient visits (RR = 0.81, 0.76–
0.86). As is true for treatment costs, the risks of
inpatient and outpatient care and ER visits are also
associated with key comorbidities like substance
abuse, anxiety disorder, ischemic heart disease, and
hypertension.
Discussion
We found a total charge of $12,797 per patient-year
for patients with bipolar disorder, which is very close
Table 1 Demographics, health-care utilization, and comorbidities of patients with bipolar disorder (BPD) in managed care
organizations
Variable
Overall patients
with BPD
(n = 67,862)
Patients on
ATYP
(n = 3,636)
Patients on
ATYP +MS
(n = 17,198)
Patients on
MS
(n = 47,028) P-value*
Age in years, mean (SD, median) 37.1 (15.0, 38.0) 34.8 (18.1, 35.0) 35.2 (15.4, 37.0) 38.0 (14.5) <0.0001
Female (%) 62.0 55.2 60.5 63.1 <0.0001
Months enrolled, mean (SD) 26.5 (14.8) 26.1 (14.7) 26.9 (14.6) 26.3 (14.8) <0.0001
Utilization and costs
Monthly total charge$, mean (SD) 1170 (2592) 1352 (4785) 1624 (2552) 990 (2331) <0.0001
Monthly total reimbursement$, mean (SD) 591 (1425) 699 (3864) 826 (1201) 497 (1105) <0.0001
Monthly BPD-Related Reimbursement$, mean (SD) 206 (395) 232 (501) 397 (567) 135 (263) <0.0001
Monthly total hospitalizations, mean (SD) 0.38 (1.3) 0.51 (1.73) 0.58 (1.51) 0.29 (1.18) <0.0001
Monthly total ER visits, mean (SD) 0.20 (0.13) 0.22 (0.73) 0.29 (0.93) 0.17 (0.65) <0.0001
Monthly total outpatient visits, mean (SD) 0.68 (1.31) 0.55 (1.13) 0.80 (1.62) 0.64 (1.47) <0.0001
Psychiatric comorbidity†
Alcohol abuse (%) 6.5 7.3 8.2 5.8 <0.0001
Substance abuse (%) 5.7 6.5 8.4 4.7 <0.0001
Anxiety disorder (%) 39.4 43.1 44.9 37.1 <0.0001
Impulse control disorder (%) 2.1 2.8 3.4 1.6 <0.0001
Personality disorder (%) 3.7 4.6 6.2 2.8 <0.0001
Eating disorder (%) 1.2 1.2 1.5 1.1 <0.0001
Other mental disorders (%) 48.0 52.5 51.6 46.4 <0.0001
Medical comorbidity†
Diabetes mellitus (%) 7.7 8.0 8.6 7.4 <0.0001
Hypertension (%) 19.1 18.9 19.9 18.8 0.0046
COPD (%) 3.4 3.9 3.8 3.2 0.002
CVD (%) 2.6 3.3 3.1 2.3 <0.0001
IHD (%) 3.6 3.9 3.6 3.6 0.6901
Arthritis (%) 2.5 2.5 2.7 2.5 0.3704
Obesity (%) 6.2 5.4 7.8 5.6 <0.0001
Charlson index scores‡ 0.29 0.33 0.30 0.28 0.0048
(range 0–14) (range 0–12) (range 0–13) (range 0–14)
*Three patient groups were compared using one-way ANOVA for continuous variables including age, month enrolled, monthly total charges, monthly outpatient visits, etc.;
chi-square tests were used for all dichotomous variables including sex, alcohol abuse, anxiety disorder, diabetes mellitus, etc.
†Patients might have multiple comorbidities during the study period.They are not mutually exclusive.
‡Charlson index scores in this study do not include the above speciﬁc comorbidities to avoid double counting.
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Table 2 Bipolar-related and comorbidity-related treatment costs and health-care utilization for patients with bipolar disorder in
managed care organizations (N = 67,862)
Category
Treatment charge
(2002 $)*
Treatment cost
(2002 $)*
(utilization) Cost (%)
Cost (2002 $)
per Unit Bipolar-related (%)
Comorbidity-
related (%)
Inpatient (LOS)† 670,905,525 297,747,412 30.9 653 10.9 20.0
(455,907)
ER Visits (n)† 65,005,632 30,145,912 3.1 109 0.3 2.8
(277,641)
Outpatient (n) 319,689,808 149,916,693 15.5 128 1.9 13.7
(1,168,293)
Mental services (n) 25,339,042 9,673,662 1.0 194 0.5 0.5
(49,925)
Physician visits (n) 294,668,335 158,545,172 16.4 56 4.2 12.3
(2,842,427)
Laboratory test (n) 7437,252 3,666,713 0.4 16 0.1 0.3
(235,616)
Other medical (n) 176,254,659 82,076,361 8.5 77 1.2 7.3
(1,066,988)
Prescription (n) 358,471,860 232,447,555 24.1 57 13.8 10.3
(4,056,337)
Total cost 1,917,772,113 964,219,478 100.0 32.8 67.2
Mean cost per patient-year‡ 12,797 6,434
*Charge (2002 $) refers to original charges in 2002 US. dollars. Cost (2002 $) refers to reimbursed amounts in 2002 dollars. All percentages for each category are based on
reimbursed cost.
†(LOS) refers to length of stay in days in hospitals, while (n) refers to numbers of health utilization units, e.g., number of ER visits, number of physician visits, number of lab tests,
number of prescription drugs, etc.
‡Mean cost per patient year was calculated as ((total cost/total number of patients)/mean enrollment months) ¥ 12.
Table 3 Summary of Poisson regression and log-linear regression results for monthly treatment costs for patients with bipolar
disorder in managed care organizations (n = 67,862)
Variables
Bipolar-related
treatment costs
Poisson model
Total treatment
costs
Poisson model
Bipolar-related
treatment costs
log-linear
Total treatment
costs
log-linear
rate ratio (95% CI) rate ratio (95% CI)
coefﬁcient
(t-statistic)
coefﬁcient
(t-statistic)
Sex (male = 1) 0.88 (0.85–0.90) 0.86 (0.84–0.89) -0.16 (-17.24†) -0.26 (-34.33)
Age (years) 1.002 (1.001–1.003) 1.003 (1.002–1.004) 0.003 (9.84†) 0.006 (20.6†)
Medications
ATYP 1.62 (1.53–1.70) 1.24 (1.17–1.31) 0.48 (23.97†) 0.23 (14.5†)
ATYP +MS 2.79 (2.72–2.86) 1.52 (1.47–1.56) 1.24 (117.7†) 0.62 (73.79†)
MS‡ 1.00 1.00 0 0
Psychiatric comorbidities
Alcohol abuse 1.30 (1.25–1.35) 1.16 (1.10–1.22) 0.30 (15.38†) 0.29 (18.6†)
Substance 1.28 (1.23–1.33) 1.44 (1.37–1.52) 0.34 (16.46†) 0.49 (29.39†)
Anxiety 1.16 (1.13–1.19) 1.15 (1.12–1.19) 0.13 (13.48†) 0.24 (31.26†)
Impulse-control 1.14 (1.07–1.22) 1.17 (1.07–1.28) 0.16 (5.14†) 0.28 (11.25†)
Personality 1.65 (1.58–1.72) 1.45 (1.37–1.53) 0.52 (21.62†) 0.37 (19.57†)
Eating 1.48 (1.38–1.59) 1.40 (1.27–1.53) 0.38 (9.41†) 0.36 (11.01†)
Other mental disorders 1.32 (1.29–1.36) 1.22 (1.18–1.26) 0.26 (27.67†) 0.23 (30.79†)
Medical comorbidities
Diabetes mellitus 1.07 (1.03–1.11) 1.34 (1.29–1.40) 0.07 (3.93*) 0.34 (23.76†)
Hypertension 1.06 (1.02–1.09) 1.25 (1.21–1.30) 0.002 (0.16) 0.26 (25.17†
Chronic obstructive
pulmonary diseases
1.14 (1.08–1.20) 1.45 (1.38–1.52) 0.04 (1.68) 0.39 (19.1†)
Cerebral-vascular disease 1.00 (0.94–1.06) 1.07 (1.01–1.13) -0.06 (-1.84) 0.19 (7.8†)
Ischemic heart disease 1.03 (0.98–1.09) 1.49 (1.42–1.56) 0.01 (0.27) 0.50 (24.99†)
Arthritis 1.02 (0.95–1.08) 1.30 (1.22–1.38) -0.04 (-1.28) 0.34 (14.77†)
Obesity 1.21 (1.16–1.26) 1.23 (1.18–1.29) 0.18 (9.54†) 0.24 (15.64†)
Charlson index scores 1.01 (1.00–1.02) 1.18 (1.17–1.19) -0.01 (-2.87*) 0.18 (45.39†)
Model goodness-of-ﬁt Scaled deviance = 0.4739 Scaled deviance = 0.4887 Adjusted R-square = 0.3245 Adjusted R-square = 0.3944
Log-likelihood = 232,279 Log-likelihood = 225,354
*P < 0.05.
†P < 0.0001.
‡Patients who received only mood stabilizers (MS) were used as the reference group in both the Poisson regression and the log-linear regression models.
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to published national estimates as discussed in the
introduction. Moreover, the total reimbursed treat-
ment cost per patient-year of $6434 is similar to the
Simon and Unutzer [18] estimate of $7200, presum-
ably because both studies were based on managed-
care-organization claims data. Not surprisingly, major
cost components for BPD patients are hospital ser-
vices, physician encounters, and prescription drugs.
Although each ER visit is expensive, the visits in total
account for a relatively small share of total treatment
cost.
The study found that 67% of treatment costs were
due to the treatment of patients’ comorbidities. More-
over, each of the psychiatric and medical comorbidities
identiﬁed individually had a signiﬁcant impact on cost.
Although this result is not surprising, it is very impor-
tant since it implies that the most expensive part of
treating a bipolar patient is not the disease itself but
rather, for example, the anxiety disorder, alcohol and
substance abuse, personality disorder, eating disorder,
diabetes mellitus, obesity, arthritis, hypertension, and
COPD that tend to be suffered concurrently by the
bipolar patient [3–15].
Compared with patients on the MS regimen,
patients taking both mood stabilizers and antipsychot-
ics had the highest treatment costs and those on antip-
sychotic monotherapy had the second highest costs.
Moreover, again compared with patients on the MS
regimen, patients on both mood stabilizers and antip-
sychotics were shown to have the highest risks of
hospitalization and ER visits, followed by those on
atypicals alone. These differences in costs and utiliza-
tion may be due to varying degrees of severity of
bipolar disorder, over which we had no control in this
study. Interestingly, patients in the ATYP group were
shown to have a lower risk of outpatient visits com-
pared to patients in the other two treatment regimens.
Our results indicate that older patients have higher
treatment costs. Bipolar disorder often begins in ado-
lescence or early adulthood and continues throughout
life [1,2]. Older patients may have developed more
medical comorbidities compared to younger patients.
Our ﬁnding is consistent with the ﬁndings in other
studies [17–22].
This study was limited to the U.S. managed care
population. Thus, ﬁndings should not be generalized
to Medicaid or other populations. Moreover, because
health care coverage varies from health plan to health
plan, the health care utilization and cost patterns in
this cohort may reﬂect the characteristics of the par-
ticular managed care health plans in our database.
Furthermore, reimbursement values may underesti-
mate treatment costs because the MCO health plans
may include some cost-sharing for outpatient mental
services and prescription drug coverage. Nor do reim-
bursement data accurately capture true drug acquisi-
tion costs due to lack of publicly available data related
to rebates or discounts from drug manufacturers.
To date, published research on bipolar-related and
comorbidity treatment costs in the managed care
Table 4 Rate ratios of hospitalizations, emergency room visits, and outpatient visits for patients with bipolar disorder based on
Poisson regression analyses (n = 67,862)
Variables
Total hospitalizations
rate ratio (95% CI)
Total ER visits
rate ratio (95% CI)
Total outpatient visits
rate ratio (95% CI)
Sex (male = 1) 0.87 (0.83–0.90) 0.72 (0.68–0.76) 0.79 (0.77–0.81)
Age (years) 1.001 (0.998–1.002) 0.99 (0.98–0.99) 1.003 (1.002–1.004)
Medications
ATYP 1.44 (1.33–1.56) 1.15 (1.04–1.27) 0.81 (0.76–0.86)
ATYP +MS 1.61 (1.54–1.68) 1.41 (1.34–1.48) 1.14 (1.11–1.17)
MS* 1.000 1.000 1.000
Psychiatric comorbidities
Alcohol abuse 1.50 (1.41–1.60) 1.24 (1.15–1.34) 1.25 (1.19–1.30)
Substance 1.85 (1.74–1.97) 2.12 (1.98–2.27) 1.39 (1.32–1.45)
Anxiety 1.27 (1.21–1.33) 1.58 (1.50–1.66) 1.18 (1.15–1.21)
Impulse-control 1.40 (1.25–1.57) 0.89 (0.77–1.03) 1.16 (1.07–1.26)
Personality 1.78 (1.66–1.90) 1.44 (1.32–1.56) 1.24 (1.17–1.30)
Eating 1.50 (1.32–1.70) 1.20 (1.04–1.38) 1.22 (1.12–1.34)
Other mental disorders 1.46 (1.39–1.53) 1.24 (1.18–1.30) 1.29 (1.25–1.32)
Medical comorbidities
Diabetes mellitus 1.44 (1.36–1.52) 1.17 (1.08–1.25) 1.34 (1.29–1.39)
Hypertension 1.40 (1.33–1.47) 1.50 (1.42–1.59) 1.31 (1.27–1.36)
Chronic obstructive pulmonary diseases 1.94 (1.81–2.06) 1.61 (1.47–1.76) 1.18 (1.12–1.24)
Cerebral-vascular disease 1.41 (1.31–1.51) 1.33 (1.20–1.47) 0.99 (0.94–1.05)
Ischemic heart disease 1.89 (1.78–2.02) 1.67 (1.53–1.81) 1.40 (1.34–1.47)
Arthritis 1.12 (1.03–1.23) 1.30 (1.16–1.44) 1.34 (1.27–1.42)
Obesity 1.17 (1.10–1.25) 1.32 (1.23–1.42) 1.24 (1.19–1.30)
Charlson index scores 1.19 (1.18–1.20) 1.08 (1.06–1.10) 1.18 (1.17–1.19)
Model goodness-of-ﬁt Scaled deviance = 0.4634 Scaled deviance = 0.4408 Scaled deviance = 0.5805
Log likelihood = 14,075 Log likelihood = 4,175 Log likelihood = 50,582
*Patients who received only mood stabilizers (MS) were used as the reference group.
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population is very limited. Since many MCO programs
cover patients with mental illnesses, the ﬁndings of this
study provide useful information for future illness
management strategies and mental health policy deci-
sions. The results from this study suggest that efforts to
control treatment costs for patients with BPD may
need to focus on patients with key psychiatric and
other medical comorbidities. Further, an effort should
be made to monitor the association between the use of
particular medications and health-care costs and
resource use.
Conclusion
Many people suffer from bipolar disorder, and the
burden that it places on health-care resources is large
and growing. Much of the expense is due to the treat-
ment of psychiatric and medical comorbidities that
often accompany bipolar disorder. Moreover, the dif-
ferent approaches to treatment of bipolar disorder
are associated with different degrees of health care
resource use and different overall treatment costs.
These cost breakdowns provide important information
for managed care organizations and others interested
in disease management and cost containment.
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